EGCG affects growth factor receptor signaling in H2111, H358, and H460 NSCLC cells. EGCG affects growth factor receptor signaling in H2111, H358, and H460.

Slides:

Advertisements

Similar presentations

Defining Epidermal Growth Factor Receptor exon 20 mutant sensitivity to tyrosine kinase inhibition Danny Rayes.

Advertisements

Supplementary Figure 1 Lapatinib nM mM pEGFR MDA-MB231 EGFR pEGFR

From: Lysophosphatidic Acid Promoting Corneal Epithelial Wound Healing by Transactivation of Epidermal Growth Factor Receptor Invest. Ophthalmol. Vis.

Inhibition of PDGFR-β downstream signaling events by flavones.

Antiproliferative effects of erlotinib correlate poorly with abundance of p-EGFR. Antiproliferative effects of erlotinib correlate poorly with abundance.

Small-molecule inhibitor QLT-0267 suppresses ILK activity and inhibits its downstream signaling. Small-molecule inhibitor QLT-0267 suppresses ILK activity.

Proline supplementation during P5CS protein knockdown suppressed GCN2 activation. Proline supplementation during P5CS protein knockdown suppressed GCN2.

Angiotensin II-induced growth of vascular smooth muscle cells requires an Src- dependent activation of the epidermal growth factor receptor1 Dirk Bokemeyer,

The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.

Deletion of the epidermal growth factor receptor in renal proximal tubule epithelial cells delays recovery from acute kidney injury Jianchun Chen, Jian-Kang.

Coactivation of Receptor Tyrosine Kinases in Malignant Mesothelioma as a Rationale for Combination Targeted Therapy Marie Brevet, MD, PhD, Shigeki Shimizu,

Overexpression of HGF decreases MET protein levels.

Leto et al., Supplementary Figure S3

AMPK induces VEGF-A production by upregulating ERK signaling.

Fig. 5. Receptor tyrosine kinase activation in response to growth factor stimulation. Receptor tyrosine kinase activation in response to growth factor.

Knocking down Wnt3 increases the cells' response to trastuzumab and reduces cells' invasiveness. Knocking down Wnt3 increases the cells' response to trastuzumab.

FeTTPS blocks tyrosine nitration of TrkA receptor and restores TrkA-Y490 phosphorylation in RGCs. A: Peroxynitrite (PN) increased TrkA tyrosine nitration.

IL-6 signaling affects response to erlotinib in head and neck (HNSCC) cells. IL-6 signaling affects response to erlotinib in head and neck (HNSCC) cells.

Phosphorylation of AMPK-Thr172 before and after metformin treatment in muscle from subjects with type 2 diabetes. Phosphorylation of AMPK-Thr172 before.

pERK ERK pSTAT1 STAT1 pSTAT3 STAT3 pAKT AKT

CML-HSA treatment activates MAPK family members ERK1/2 and p38 but not JNK. Samples were taken at the indicated times after 100 μg/ml CML-HSA exposure.

eNOS regulated IR-induced NO generation and EGFR signal activation.

The dynamics of Akt activation in cultured human keratinocytes.

Curcumin-generated ROS activates Chk1 and Chk2 kinases.

OPCML-associated RTK modulation affects downstream signaling.

The effects of the FASN blocker C75 on cell growth and survival (A, E, and F), on expression/phosphorylation of PI3K and MAPK signaling proteins and on.

Recognition of naturally processed HTLV-1 Tax protein derived from HAM patient's PBMC. A, HTLV-1 Tax protein content was evaluated by Western blot analysis.

Effects of knockdown of DDR1 levels on proliferation and apoptosis.

FOXO3a phosphorylation and expression.

Effect of LY on phosphorylation of various MAP kinase substrates in HeLa cells in vitro. Effect of LY on phosphorylation of various MAP kinase.

BME treatment increases granzyme B expression in NK 3.3 cells.

AG1024 reduced the level of tyrosyl-phosphorylated proteins, including Erk2. AG1024 reduced the level of tyrosyl-phosphorylated proteins, including Erk2.

DNA damage signaling regulates mutant p53 ubiquitination.

Imatinib mesylate inhibits PDGF-mediated ERK and Akt activation.

ALDH1A3 is mainly responsible for the ALDH activity in two human cholangiocarcinoma lines. ALDH1A3 is mainly responsible for the ALDH activity in two human.

Down-regulation of the erbB-2 receptor by trastuzumab decreases Akt kinase activation but not MAPK activation. Down-regulation of the erbB-2 receptor by.

Effects of visfatin on the cell proliferation and phosphorylation of ERK, Akt, and GSK-3β proteins in HCC cells. Effects of visfatin on the cell proliferation.

Ectopic expression of miR-187 in MCF7 cells results in increased migration, invasion, and anchorage-independent colony formation. Ectopic expression of.

VEGF expression in neoplastic and normal prostate tissue.

MiR-200c is a PI3K–AKT signaling pathway regulator in CRC

Expression of CRC stem cell markers and L1 in CRC cells.

Expression of versican promoted breast cancer cell self-renewal through enhanced EGFR/AKT/GSK-3β (S9P) signals. Expression of versican promoted breast.

Curcumin suppresses the expression of antiapoptotic proteins in multiple myeloma cells. Curcumin suppresses the expression of antiapoptotic proteins in.

A. A. Honokiol inhibits TNF-induced NF-κB activation, IκBα phosphorylation, and IκBα degradation. Honokiol inhibits TNF-induced activation of NF-κB. H1299.

MDA-468TR-PTEN (with and without 100 ng/ml doxycycline) and MDA-468TR-vector (with dox) were serum starved overnight and the following day treated for.

ERK reactivation following EGFR TKI treatment.

A, Western blot analysis of vascular endothelial growth factor-C (VEGF-C). A, Western blot analysis of vascular endothelial growth factor-C (VEGF-C). Concentrated.

PKCζ is tyrosine phosphorylated by EGF and contributes to EGF-induced activation of ERK in Mef cells. PKCζ is tyrosine phosphorylated by EGF and contributes.

Expression of dominant-negative RasN17 completely suppresses Ras activation in Rh1 cells. Expression of dominant-negative RasN17 completely suppresses.

Changes in signal transduction pathway induced by gefitinib.

by Dana S. Levy, Jason A. Kahana, and Rakesh Kumar

Increased levels of acetylated histone H3 are observed in normal PBMCs and circulating tumor cells obtained from patients post-depsipeptide treatment.

Characterization of DNA-PK and PARP-1 levels and activities in the cell lines studied. Characterization of DNA-PK and PARP-1 levels and activities in the.

Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors.

The combination of trastuzumab and SU11274 abrogate Akt phosphorylation. The combination of trastuzumab and SU11274 abrogate Akt phosphorylation. Serum-starved.

Prevalence of germline T790M.

ODC protein expression in paired benign and cancer tissue obtained from patients with PCA. The protein expression was measured by immunoblot analysis in.

Effects of UVB on AKT in SKH-1 mouse epidermis.

Western blot analysis for bFGF expression in human glioma cell lines.

SAHA blocks IR-induced increase of RAD51 protein in MM cells.

Differential effects of the RAF inhibitor PLX4032 in BRAF-mutant melanoma, thyroid, and colorectal cancer cell lines. Differential effects of the RAF inhibitor.

Effect of bevacizumab on the proliferation of A2780 cells.

Double knockdown of HER2/EGFR abolishes HPSE nucleolar localization in 231BR3 cells. Double knockdown of HER2/EGFR abolishes HPSE nucleolar localization.

Expression and induction of HER2 and HPSE in 231BMBC cells.

Effect of MIF siRNA on the production of MMP-13 induced by LPA

Increased growth factor receptor expression in lungs and tumors of hypoxic mice. Increased growth factor receptor expression in lungs and tumors of hypoxic.

Posttranslational phosphorylation of p53 by platinum drugs in ovarian tumor cells. Posttranslational phosphorylation of p53 by platinum drugs in ovarian.

Regulation of signaling by wild-type and oncogenic Ras.

Depletion of murine Dnmt proteins after 5-Aza-CdR treatment.

T3 or T4 induces MAPK activation in myeloma cells.

Presentation transcript:

EGCG affects growth factor receptor signaling in H2111, H358, and H460 NSCLC cells. EGCG affects growth factor receptor signaling in H2111, H358, and H460 NSCLC cells. Cells were stimulated with either HGF at 33 ng/mL (A) or EGF at 100 ng/mL (B). As noted, cells were pretreated with EGCG 10 μmol/L to 40 μmol/L for 4 h (A and B) or 2 mmol/L erlotinib for 1 h (C). Cell lysates were collected and subjected to SDS-PAGE and Western blotting, and analyzed with phospho-specific antibodies to the c-Met receptor (pMet), Akt (p-Akt), Erk1/2 (pErk), and EGFR (pEGFR). Tubulin was used as a control for loading. Shawn A. Milligan et al. Clin Cancer Res 2009;15:4885-4894 ©2009 by American Association for Cancer Research